|Trade names||Cefzil, Cefproz, others|
|Elimination half-life||1.3 hours|
|Chemical and physical data|
|Molar mass||389.427 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Cefprozil is a second-generation cephalosporin antibiotic. It can be used to treat ear infections, skin infections, and other bacterial infections. It comes as a tablet and as a liquid suspension.
Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article has shown no increased risk for cross-allergy for cefprozil and several other second-generation or later cephalosporins.
It was patented in 1983 and approved for medical use in 1992.
Spectrum of bacterial susceptibility and resistance
Currently bacteria like Enterobacter aerogenes, Morganella morganii and Pseudomonas aeruginosa are resistant to cefprozil, while Salmonella enterica serotype Agona and streptococci are susceptible to cefprozil. Some bacteria like Brucella abortus, Moraxella catarrhalis and Streptococcus pneumoniae have developed resistance towards cefprozil in varying degrees. Detailed minimum inhibition concentration information is given by the Cefprozil Susceptibility and Resistance Data sheet.
Displacement of the allylic chloride in intermediate (1) with triphenylphosphine gives the phosphonium salt (2). This functionality is then converted to its ylide; condensation with acetaldehyde then leads to the vinyl derivative (3); deprotection then gives cefprozil. Semisynthetic oral cephalosporin consisting of ~90:10 Z/E isomeric mixture.
It is marketed under the trade names Cefzil and Cefproz. In Europe it is marketed using the trade names Procef and Cronocef.
- Pichichero, ME (February 2006). "Cephalosporins can be prescribed safely for penicillin-allergic patients". J Fam Pract. 55 (2): 106–12. PMID 16451776.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495.
- "Cefprozil Susceptibility and Resistance Data" (PDF). Retrieved 23 July 2013.
- H. Hoshi et al., DE 3402642 ; eidem, U.S. Patent 4,520,022 (1984, 1985 both to Bristol-Myers).
- Naito, T; Hoshi, H; Aburaki, S; Abe, Y; Okumura, J; Tomatsu, K; Kawaguchi, H (1987). "Synthesis and structure-activity relationships of a new oral cephalosporin, BMY-28100 and related compounds". The Journal of Antibiotics. 40 (7): 991–1005. doi:10.7164/antibiotics.40.991. PMID 3624077.
- M. A. Kaplan et al., U.S. Patent 4,727,070 (1988 to Bristol-Myers).
- Cefprozil MedlinePlus Drug Information
|This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.|